Alpha 1 Antitrypsin Deficiency Clinical Trials

A listing of Alpha 1 Antitrypsin Deficiency medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 27 clinical trials
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

The purpose of this study is to develop and evaluate the usefulness of MRI using 129Xe gas for regional assessment of pulmonary function. Specifically, three forms of 129Xe MRI contrast will be the investigators focus - 1) imaging of the 129Xe ventilation distribution, 2) imaging the alveolar microstructure via the …

emphysema
pulmonary disease
hypertension
assisted ventilation
Accepts healthy volunteers
  • 288 views
  • 21 Oct, 2021
  • 1 location
An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis (FALL)

other chronic liver diseases like autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hereditary hemochromatosis and alpha-1-antitrypsin deficiency and may also develop

Accepts healthy volunteers
  • 0 views
  • 29 Apr, 2022
  • 1 location
Alpha-1 Research Registry

The Alpha-1 Research Registry is a confidential database made up of individuals diagnosed with Alpha-1 Antitrypsin Deficiency (Alpha-1) and individuals identified as Alpha-1 carriers. The

alpha1-proteinase inhibitor (human)
deficiency
  • 46 views
  • 17 Feb, 2022
  • 1 location
EARCO REGISTRY. History Of Patients With Alpha-1 Antitrypsin (EARCO)

European Alpha-1 Research Collaboration (EARCO) is a pan-European network committed to promoting clinical research and education in alpha-1 antitrypsin deficiency (AATD). The core project is the

emphysema
protease inhibitor
alpha1-proteinase inhibitor (human)
deficiency
  • 22 views
  • 26 Feb, 2022
Alpha-1 Coded Testing(ACT) Study (ACT)

The Alpha-1 Coded Testing (ACT) Study was established to study genetic testing and outcomes of individuals at risk for alpha-1 antitrypsin deficiency.

Accepts healthy volunteers
alpha1-proteinase inhibitor (human)
deficiency
  • 186 views
  • 23 Jan, 2022
  • 1 location
Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) (LOGIC)

Cholestasis is a condition in which bile is not properly transported from the liver to the small intestine. Cholestasis can be caused by an array of childhood diseases, including the genetic diseases Alagille syndrome (ALGS), alpha-1 antitrypsin (a-1AT) deficiency, bile acid synthesis and metabolism defects, and progressive familial intrahepatic cholestasis …

bile salts
small intestine
bile acid
cholestasis
liver disease
  • 200 views
  • 02 May, 2022
  • 13 locations
Role of Genetic Factors in the Development of Lung Disease

This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible for processes …

ct scan
x-rays
chest x-ray
sarcoidosis
bronchoscopy
  • 301 views
  • 28 Jul, 2022
  • 1 location
Czech AATD Registry

accelerates active cigarette smoking. Patients with alpha-1-antitrypsin deficiency may also have liver cirrhosis, vasculitis, skin or intestinal disorders. The AATD Registry is a non-interventional

emphysema
cigarette smoke
alpha1-proteinase inhibitor (human)
cirrhosis
deficiency
  • 0 views
  • 24 Mar, 2022
Alpha-1 Antitrypsin Deficiency Adult Liver Study

The investigators hypothesize that there is liver injury (inflammation, fibrosis, cirrhosis) in adults with Alpha-1 Antitrypsin Deficiency (AATD), which is asymptomatic, under-recognized, and

liver injury
liver disease
liver study
alpha1-proteinase inhibitor (human)
cirrhosis
  • 262 views
  • 21 Mar, 2022
  • 3 locations
Respreeza® Self-administration and Learning Program (AmAREtTI Study) (AmAREtTI)

According to the Respreeza® Summary of Product Characteristics, the initial infusions must be administered under the supervision of a health professional experienced in the treatment of alpha-1

self-administration
alpha1-proteinase inhibitor (human)
deficiency
  • 49 views
  • 09 Aug, 2022
  • 10 locations